Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,263 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo first Clear all

Conditions: Chronic Cough
Interventions: ADX-629, Placebo; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 14
States / cities: San Diego, California • San Jose, California • Hollywood, Florida + 11 more

Conditions: Stress Disorders, Post-Traumatic, Combat Disorders, Sleep Disorders
Interventions: prazosin hydrochloride, placebo; Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Seattle, Washington • Tacoma, Washington

Conditions: Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder, Mood Disorders With Psychotic Features
Interventions: Olanzapine, Amantadine, Olanzapine and placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy Volunteers
Interventions: AZD2373 subcutaneous injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Pharmacokinetics, Safety, Tolerability
Interventions: 5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo; Drug
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Sudden Sensorineural Hearing Loss
Interventions: Statin, methylprednisolone, dexamethasone, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metastatic Breast Cancer
Interventions: ABT-869, paclitaxel, Placebo for ABT-869; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: San Francisco, California • Harvey, Illinois

Conditions: Autism Spectrum Disorder (ASD)
Interventions: Omega-3 Fatty Acid; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dental Caries
Interventions: C16G2, Placebo; Drug · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Indianapolis, Indiana • Kalispell, Montana • New York, New York + 2 more

Conditions: Smoking Cessation
Interventions: Bupropion SR, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: PF-04634817 Placebo, PF-04634817; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Post-Amputation Phantom Limb Pain
Interventions: Cryoneurolysis, Sham Comparator; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Palo Alto, California • San Diego, California • Gainesville, Florida + 2 more

Conditions: Colonic Polyp, Colonoscopy, Complication, Recurrence
Interventions: Cold snare EMR, Hot snare EMR, Eleview injection, Placebo injection; Procedure
Lead sponsor: White River Junction Veterans Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: White River Junction, Vermont

Conditions: Metabolic Bone Disease
Interventions: Lanthanum Carbonate (Fosrenol), placebo; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Type 2 Diabetes Mellitus, Hypertension
Interventions: Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT); Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Malignant Glioma
Interventions: Nuvigil®, Placebo; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Epilepsy
Interventions: TAK-935, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: SARS CoV 2 Infection
Interventions: EDP-235, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
Interventions: glutamic acid, placebo; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 3 Years to 20 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 6
States / cities: Fort Myers, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 3 more

Conditions: Nocturia
Interventions: Placebo, Paxerol - Dose Level 1, Paxerol - Dose Level 2, Paxerol - Dose Level 3; Other · Drug
Lead sponsor: Wellesley Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Brooklyn, New York • Harrison, New York • New York, New York

Conditions: Healthy Volunteer
Interventions: ABBV-859, Placebo for ABBV-859; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Acute Liver Failure
Interventions: N-acetylcysteine (NAC), Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more

Conditions: Acute Kidney Injury
Interventions: ANG-3777, Placebo; Drug
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 23
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 18 more

Conditions: Asthma, Distal Lung Inflammation
Interventions: Flunisolide-HFA, Flunisolide-CFC; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)

Study of Amantadine for Weight Stabilization During Olanzapine Treatment

A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers

Oral Statins and Protection From Hearing Loss

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders

Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects

Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy

First In Human Study Of Increasing Oral Doses Of PF-04634817

Cryoanalgesia to Treat Post-Amputation Phantom Limb Pain: A Department of Defense Funded Multicenter Study

Cold Snare Endoscopic Mucosal Resection Trial

The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

Nuvigil or Placebo in Newly Diagnosed Malignant Glioma

TAK-935 Multiple Rising Dose Study in Healthy Participants

A Study of EDP-235 in Healthy Subjects

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial

A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants

Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

Mentored Patient-Oriented Research Career Development Award